U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C7H10NO7P2.2Na.5H2O
Molecular Weight 700.2646
Optical Activity NONE
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RISEDRONATE SODIUM HEMI-PENTAHYDRATE

SMILES

O.O.O.O.O.[Na+].[Na+].OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O.OC(CC2=CN=CC=C2)(P(O)(O)=O)P(O)([O-])=O

InChI

InChIKey=HYFDYHPNTXOPPO-UHFFFAOYSA-L
InChI=1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/risedronate.html http://www.wikidoc.org/index.php/Risedronate http://www.rxlist.com/actonel-drug.htm

Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACTONEL

Approved Use

ACTONEL is indicated for the treatment and prevention of osteoporosis and Paget’s disease of bone in men and women.

Launch Date

1998
Primary
ACTONEL

Approved Use

ACTONEL is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of ≥ 7.5 mg prednisone or equivalent) for chronic diseases.

Launch Date

1998
Primary
ACTONEL

Approved Use

ACTONEL is indicated for treatment of Paget’s disease of bone in men and women.

Launch Date

1998
Primary
ACTONEL

Approved Use

ACTONEL is indicated for treatment to increase bone mass in men with osteoporosis.

Launch Date

1998
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.05 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISEDRONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.49 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISEDRONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.61 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISEDRONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.362
unhealthy, 41.6±15.7
n = 60
Health Status: unhealthy
Condition: Glucocorticoid-induced bone mineral density loss prevention
Age Group: 41.6±15.7
Sex: M+F
Population Size: 60
Sources: Page: p.362
Disc. AE: Skin rash, Gastrointestinal upset...
AEs leading to
discontinuation/dose reduction:
Skin rash (1.7%)
Gastrointestinal upset (1.7%)
Sources: Page: p.362
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.9
unhealthy, 50 - 86
n = 613
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 86
Sex: F
Population Size: 613
Sources: Page: p.9
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.3%)
Sources: Page: p.9
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.9
unhealthy, 50 - 86
n = 616
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 86
Sex: F
Population Size: 616
Sources: Page: p.9
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (0.2%)
Sources: Page: p.9
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources: Page: p.9
unhealthy, 50 - 86
n = 616
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 86
Sex: F
Population Size: 616
Sources: Page: p.9
Disc. AE: Vomiting, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Vomiting (1%)
Diarrhea (1%)
Sources: Page: p.9
150 mg 1 times / month multiple, oral
Recommended
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources: Page: p.10
unhealthy, 50 - 88
n = 650
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 88
Sex: F
Population Size: 650
Sources: Page: p.10
Disc. AE: Abdominal pain upper, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Abdominal pain upper (2.5%)
Diarrhea (0.8%)
Vomiting (0.3%)
Sources: Page: p.10
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.10
unhealthy, 50 - 88
n = 642
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 88
Sex: F
Population Size: 642
Sources: Page: p.10
Disc. AE: Abdominal pain upper, Vomiting...
AEs leading to
discontinuation/dose reduction:
Abdominal pain upper (1.4%)
Vomiting (0.3%)
Sources: Page: p.10
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal upset 1.7%
Disc. AE
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.362
unhealthy, 41.6±15.7
n = 60
Health Status: unhealthy
Condition: Glucocorticoid-induced bone mineral density loss prevention
Age Group: 41.6±15.7
Sex: M+F
Population Size: 60
Sources: Page: p.362
Skin rash 1.7%
Disc. AE
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.362
unhealthy, 41.6±15.7
n = 60
Health Status: unhealthy
Condition: Glucocorticoid-induced bone mineral density loss prevention
Age Group: 41.6±15.7
Sex: M+F
Population Size: 60
Sources: Page: p.362
Diarrhea 0.3%
Disc. AE
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.9
unhealthy, 50 - 86
n = 613
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 86
Sex: F
Population Size: 613
Sources: Page: p.9
Vomiting 0.2%
Disc. AE
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.9
unhealthy, 50 - 86
n = 616
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 86
Sex: F
Population Size: 616
Sources: Page: p.9
Diarrhea 1%
Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources: Page: p.9
unhealthy, 50 - 86
n = 616
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 86
Sex: F
Population Size: 616
Sources: Page: p.9
Vomiting 1%
Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources: Page: p.9
unhealthy, 50 - 86
n = 616
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 86
Sex: F
Population Size: 616
Sources: Page: p.9
Vomiting 0.3%
Disc. AE
150 mg 1 times / month multiple, oral
Recommended
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources: Page: p.10
unhealthy, 50 - 88
n = 650
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 88
Sex: F
Population Size: 650
Sources: Page: p.10
Diarrhea 0.8%
Disc. AE
150 mg 1 times / month multiple, oral
Recommended
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources: Page: p.10
unhealthy, 50 - 88
n = 650
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 88
Sex: F
Population Size: 650
Sources: Page: p.10
Abdominal pain upper 2.5%
Disc. AE
150 mg 1 times / month multiple, oral
Recommended
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources: Page: p.10
unhealthy, 50 - 88
n = 650
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 88
Sex: F
Population Size: 650
Sources: Page: p.10
Vomiting 0.3%
Disc. AE
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.10
unhealthy, 50 - 88
n = 642
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 88
Sex: F
Population Size: 642
Sources: Page: p.10
Abdominal pain upper 1.4%
Disc. AE
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources: Page: p.10
unhealthy, 50 - 88
n = 642
Health Status: unhealthy
Condition: Postmenopausal osteoporosis
Age Group: 50 - 88
Sex: F
Population Size: 642
Sources: Page: p.10
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials.
2001
Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature.
2001 Aug
Anabolic agents for treating postmenopausal osteoporosis.
2001 Dec
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
2001 Dec
Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.
2001 Dec 21
[Therapy of osteoporosis. Risk factors alone are not an indication].
2001 Dec 6
[Fluorides and bisphosphonates in the treatment of osteoporosis].
2001 Jul
New possibilities for diagnosis and treatment of osteoporosis.
2001 Jul-Aug
Ocular adverse effects of alendronic acid.
2001 Jun
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
2001 Nov
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
2001 Nov
The role of serial bone mineral density testing for osteoporosis.
2001 Nov
Role of alendronate and risedronate in preventing and treating osteoporosis.
2001 Nov
A method to assess the proportion of treatment effect explained by a surrogate endpoint.
2001 Nov 15
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
2001 Nov 22
Osteoporosis in men.
2001 Nov-Dec
Risedronate treatment and extended fracture protection in postmenopausal women.
2001 Nov-Dec
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
2001 Oct
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
2001 Oct
Alendronate for the treatment of osteoporosis in men.
2001 Oct
Paget's disease of the spine and its management.
2001 Oct
Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
2001 Oct
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.
2001 Oct
[Osteoporosis. Fracture as alarm signal].
2001 Oct 11
Pharmacologic therapy for the treatment and prevention of osteoporosis.
2001 Sep
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
2001 Sep 1
Evaluation and treatment of postmenopausal osteoporosis.
2001 Sep 25
[Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
2001 Sep 6
Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
2002
The underuse of therapy in the secondary prevention of hip fractures.
2002
Development of bisphosphonates.
2002
Direct effects of bisphosphonates on breast cancer cells.
2002
[Osteoporosis - Evidence based therapy].
2002 Apr
Risedronate for the prevention of fractures in postmenopausal osteoporosis.
2002 Apr
[Episcleritis secondary to risedronate].
2002 Apr 27
[When osteoporosis first manifests itself. Without therapy the next fracture threatens].
2002 Apr 4
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
2002 Aug
Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.
2002 Jan
Bone quality: getting closer to a definition.
2002 Jul
Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.
2002 Jul
Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
2002 Jul
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
2002 Jul 4
[Risedronate: clinical usage].
2002 Mar
Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
2002 Mar
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
2002 Mar
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
2002 Mar 2
Gateways to clinical trials.
2002 May
The cost utility of bisphosphonate treatment in established osteoporosis.
2002 May
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
2002 May 28
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.
2002 May 6
Patents

Sample Use Guides

Treatment of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week, 75 mg two consecutive days each month, 150 mg once-a-month. Prevention of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week. Men with Osteoporosis: 35 mg once-a-week. Glucocorticoid-Induced Osteoporosis: 5 mg daily. Paget’s Disease: 30 mg daily for 2 month.
Route of Administration: Oral
The antimalarial activities of risedronate, one of the most potent bisphosphonates clinically used to treat bone resorption diseases, against blood stages of Plasmodium falciparum (50% inhibitory concentration [IC50] of 20.3±1.0 μM).
Name Type Language
RISEDRONATE SODIUM HEMI-PENTAHYDRATE
Common Name English
SODIUM TRIHYDROGEN (1-HYDROXY-2-(3-PYRIDYL)ETHYLIDENE)DIPHOSPHONATE HEMI-PENTAHYDRATE
Common Name English
RISEDRONATE SODIUM HEMIPENTAHYDRATE
Common Name English
SODIUM RISEDRONATE HYDRATE [JAN]
Common Name English
PHOSPHONIC ACID, P,P'-(1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS-, SODIUM SALT, HYDRATE (2:2:5)
Common Name English
RISEDRONIC ACID MONOSODIUM SALT HEMIPENTAHYDRATE
Common Name English
RISEDRONATE SODIUM 2.5-HYDRATE [EP MONOGRAPH]
Common Name English
SODIUM RISEDRONATE HYDRATE
JAN  
Common Name English
Code System Code Type Description
DRUG BANK
DBSALT001515
Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023
PRIMARY
DAILYMED
HU2YAQ274O
Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023
PRIMARY
PUBCHEM
11954322
Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023
PRIMARY
SMS_ID
100000091405
Created by admin on Sat Dec 16 03:14:00 GMT 2023 , Edited by admin on Sat Dec 16 03:14:00 GMT 2023
PRIMARY
RXCUI
1356127
Created by admin on Sat Dec 16 03:14:00 GMT 2023 , Edited by admin on Sat Dec 16 03:14:00 GMT 2023
PRIMARY RxNorm
CAS
329003-65-8
Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023
PRIMARY
EVMPD
SUB26270
Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023
PRIMARY
FDA UNII
HU2YAQ274O
Created by admin on Sat Dec 16 03:13:59 GMT 2023 , Edited by admin on Sat Dec 16 03:13:59 GMT 2023
PRIMARY